What does Enliven Therapeutics, Inc. do?

Jun 22 2025 07:20 PM IST
share
Share Via
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare inherited genetic disorders of hemoglobin. It has a market cap of approximately $1.07 billion and reported a net profit loss of $29 million as of March 2025.
Overview:
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for rare inherited genetic disorders of hemoglobin, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.

Financial Snapshot:
Most recent Net Profit: -29 Million (Quarterly Results - Mar 2025)
Market cap: USD 1,069.71 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Dividend Yield: 0.00%
Debt Equity: -1.00
Return on Equity: -33.20%
Price to Book: 3.71

Contact Details:
Address: 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA : 02116
Tel: 1 617 2062020
Website: https://imaratx.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News